“in the next year or so whether or not its two lead programs, an APOL1 directed kidney drug and another aimed at SLC six a 19, are good enough to pass phase two clinical trial scrutiny”
→ Read the source episode
Both APOL1 and SLC6A19 programs complete phase two trials and results are publicly disclosed showing whether they met primary endpoints.
Maize Therapeutics will have initiated a pivotal study on APOL1 and advanced other programs through mid-stage development by August 2027.
Heather Turner predicts LB Pharma will be on the cusp of schizophrenia approval, have successful bipolar depression phase three data, and positive phase two adjunctive MDD data by 2029.
Avalon will initiate Phase 3 trials for APL1 and APO2 following Phase 2 data readouts in 2027
Heather Turner predicts LB102 will demonstrate efficacy across multiple serious neuropsychiatric indications beyond schizophrenia.
Avalon will have Phase 2b data readout for APL1 (inhaled pirfenidone) in the second half of 2027
Avalon will have Phase 2 data readout for APO2 (inhaled nintedanib) in late 2027
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.